CITY VIEW GREEN HOLDINGS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2022 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED)

Notice To Reader

The accompanying unaudited condensed interim consolidated financial statements of City View Green Holdings Inc. (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) Unaudited

	As at March 31, 2022			As at December 31, 2021		
ASSETS						
Current assets						
Cash and cash equivalents	\$	7,055	\$	42,655		
Amounts receivable (note 5)		79,000		88,155		
Prepaid rent and deposit		52,177		78,202		
Promissory note receivable (note 6)		369,908		364,333		
Total current assets		508,140		573,345		
Non-current assets						
Plant and equipment (note 7)		1,925,865		2,026,721		
Right-of-use assets (note 8)		2,413,981		2,496,310		
Total assets	\$	4,847,986	\$	5,096,376		
EQUITY AND LIABILITIES						
Current liabilities						
Accounts payable and accrued liabilities (note 9)	\$	1,584,837	\$	1,530,856		
Promissory note payable (note 10)		241,868		236,246		
Loans payable (note 11)		238,435		233,720		
Current portion of lease liabilities (note 12)		161,516		156,378		
Due to related parties (note 16)		20,000		20,000		
Total current liabilities		2,246,656		2,177,200		
Non-current liabilities						
Loans payable (note 11)		40,000		40,000		
Lease liabilities (note 12)		2,759,252		2,801,611		
Total liabilities		5,045,908		5,018,811		
Equity						
Share capital (note 13)		30,634,057		30,298,577		
Shares to be issued		76,789		351,789		
Contributed surplus (note 14)		8,885,793		8,665,993		
Deficit		(39,794,561)		(39,238,794)		
Total equity		(197,922)		77,565		
Total equity and liabilities	\$	4,847,986	\$	5,096,376		

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Nature of operations and going concern (note 1) Subsequent events (note 18)

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars) Unaudited

		ree Months Ended March 31, 2022	 ee Months Ended arch 31, 2021
Revenue	\$	60,720	\$
Expenses			
Consulting (note 16)		207,498	120,819
Professional fees		49,325	22,311
Rent		(13,332)	11,379
General and administration		53,233	34,474
Share-based compensation (note 14)		18,500	66,000
Supplies		23,232	-
Depreciation and amortization (notes 7 and 8)		209,079	117,381
Advertising and promotion		-	1,866
Interest on loans and promissory notes payable (notes 10 and 11)		10,338	10,151
Interest on lease liabilities (note 12)		95,734	100,249
Total expenses		653,607	484,630
Net loss before interest and undernoted items		(592,887)	(484,630)
Interest income (note 6)		5,575	6,650
Gain (loss) on debt settlement (note 13)		31,545	(27,055)
Share of loss in associate		-	(16,396)
Net loss and comprehensive loss for the period	\$	(555,767)	\$ (521,431)
Basic and diluted net comprehensive loss per share (note 17)	\$	(0.00)	\$ (0.00)
Weighted average number of common shares outstanding - basic and diluted	т	35,101,881	 58,649,464

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Cash Flows
(Expressed in Canadian Dollars) Unaudited

	nree Months Ended March 31, 2022	ee Months Ended larch 31, 2021
Operating activities		
Net loss for the period	\$ (555,767)	\$ (521,431)
Adjustments for:	, ,	,
Depreciation and amortization	209,079	117,381
Share-based compensation	18,500	66,000
Accrued interest	4,763	3,501
Interest expense on lease liabilities	95,734	100,249
(Gain) loss on debt settlement	(31,545)	27,055
Share of loss in associate	-	16,396
Changes in non-cash working capital items:		
Amounts receivable	9,155	(44,335)
Prepaid rent and deposit	26,025	(3,185)
Accounts payable and accrued liabilities	142,305	(82,899)
Net cash used in operating activities	(81,751)	(321,268)
Investing activities		
Purchase of plant and equipment	(25,894)	(500,649)
Repayment of lease liabilities	(132,955)	(132,955)
Repayment of promissory note receivable	- '	157,057
Net cash used in investing activities	(158,849)	(476,547)
Financing activities		
Proceeds from issuance of units, net of share issue costs	205,000	360,000
Proceeds from warrants exercised	-	5,000
Proceeds from promissory note payable	-	82,778
Advances from related parties	-	108,943
Shares to be issued	-	100,000
Net cash provided by financing activities	205,000	656,721
Net change in cash and cash equivalents	(35,600)	(141,094)
Cash and cash equivalents, beginning of period	42,655	152,577
Cash and cash equivalents, end of period	\$ 7,055	\$ 11,483

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Changes in Equity (Expressed in Canadian Dollars) Unaudited

	Share	е са	pital					
	Number of shares		Amount	Shares to be issued	C	ontributed surplus	Deficit	Total
Balance, December 31, 2020	247,461,530	\$	28,500,186	\$ 1,384,053	\$	7,794,193	\$ (34,615,469) \$	3,062,963
Units issued for cash	11,400,000		570,000	(210,000)		-	· · · · · ·	360,000
Fair value of warrants	, <u> </u>		(155,000)	- ,		155,000	-	-
Common shares issued for debt settlement	1,082,197		119,042	-		<u>-</u> '	-	119,042
Issued on exercise of warrants	100,000		7,400	-		(2,400)	-	5,000
Share-based payments	<u>-</u>		-	-		66,000	-	66,000
Net loss for the period	-		-	-		- 1	(521,431)	(521,431)
Balance, March 31, 2021	260,043,727	\$	29,041,628	\$ 1,174,053	\$	8,012,793	\$ (35,136,900) \$	3,091,574
Balance, December 31, 2021	283,412,270	\$	30,298,577	\$ 351,789	\$	8,665,993	\$ (39,238,794) \$	77,565
Units issued for cash	9,600,000		480,000	(275,000)		-	-	205,000
Fair value of warrants	· - ·		(201,300)	- ,		201,300	-	-
Common shares issued for debt settlement	1,261,784		` 56,̈780 [′]	-		-	-	56,780
Share-based payments	· - ·		-	-		18,500	-	18,500
Net loss for the period	-		-	-		- 1	(555,767)	(555,767)
Balance, March 31, 2022	294,274,054	\$	30,634,057	\$ 76,789	\$	8,885,793	\$ (39,794,561) \$	(197,922)

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Unaudited

1. Nature of operations and going concern

City View Green Holdings Inc. ("City View" or the "Company") was incorporated pursuant to the Canada Business Corporations Act on February 5, 2008. The Company continued into British Columbia from the jurisdiction of Canada, under the BCBCA, on February 18, 2011. On February 27, 2019, the Company completed a reverse take-over business combination with 2590672 Ontario Inc. ("2590672 Ontario") wherein the Company acquired 100% of the issued and outstanding common shares of 2590672 Ontario and began trading on the Canadian Securities Exchange ("Exchange") under the symbol "CVGR". The Company's registered office is located at 1173 Dundas Street East, Suite 132, Toronto, Ontario, M4M 3P1.

These unaudited condensed interim consolidated financial statements reflect the continuation of the financial position, operating results and cash flows of the Company's legal subsidiary, 2590672 Ontario.

The unaudited condensed interim consolidated financial statements have been prepared using accounting policies applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they become due. As at March 31, 2022, the Company is still in the development stage, has accumulated losses of \$39,794,561 since its inception and expects to incur further losses in the development of its business. These conditions raise material uncertainties which cast significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. While the Company is continuing its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds for operations. The unaudited condensed interim consolidated financial statements do not reflect adjustments to the carrying values and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern, and such adjustments may be material.

On April 30, 2021, the Company received the cannabis processing license from Health Canada. The processing license allows the Company to produce cannabis edibles and related products and will allow the Company to conduct development activities, including the formulation of proprietary cannabis infused edibles. On April 21, 2022, the Company also received its cannabis research licence under Health Canada.

The Company's operations could be significantly adversely affected by the effects of a widespread global outbreak of a contagious disease, including the recent outbreak of respiratory illness caused by COVID-19. The Company cannot accurately predict the impact COVID-19 will have on its operations and the ability of others to meet their obligations with the Company, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect the Company's operations and ability to finance its operations.

Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Unaudited

2. Basis of presentation

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by IASB and interpretations issued by IFRIC.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRSs issued and outstanding as of May 30, 2022, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual financial statements as at and for the year ended December 31, 2021. Any subsequent changes to IFRS that are given effect in the Company's annual financial statements for the year ending December 31, 2022 could result in restatement of these unaudited condensed interim consolidated financial statements.

3. Significant accounting judgments, estimates and assumptions

The preparation of the consolidated financial statements using accounting policies consistent with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. The preparation of the consolidated financial statements also requires management to exercise judgment in the process of applying the accounting policies.

Critical accounting estimates

Share-based compensation – management is required to make a number of estimates when determining the compensation expense resulting from share-based transactions, including the forfeiture rate and expected life of the instruments.

Warrants – management is required to make a number of estimates when measuring the value of warrants including expected life of the instruments.

Plant and equipment and right-of-use assets - management is required to estimate the useful lives and residual value of property, plant and equipment which are included in the consolidated statements of financial position and the related depreciation included in the consolidated statements of loss.

Recoverability of promissory notes receivable – Management's assessment of whether indicator of write off the receivable are present requires judgment based on facts and circumstances at reporting period ends.

Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Unaudited

3. Significant accounting judgments, estimates and assumptions (continued)

Critical judgments in applying accounting policies

Income taxes – measurement of income taxes payable and deferred income tax assets and liabilities requires management to make judgments in the interpretation and application of the relevant tax laws. The actual amount of income taxes only become final upon filing and acceptance of the tax return by the relevant authorities, which occurs subsequent to the issuance of the consolidated financial statements.

Going concern – the assessment of the Company's ability to continue as a going concern involves judgment regarding future funding available for its operations and working capital requirements as discussed in note 1.

Impairment assessment of investment in associate – Management's assessment as to whether there is any objective evidence that its net investment in the associate is impaired. Management must determine whether there has been a loss event that has an impact of the estimated future cash flows from the net investment that can be reliably estimated. Objective evidence that the net investment is impaired includes observable data that comes to the attention of the entity.

Impairment of plant and equipment and right-of-use assets - assessing whether indicators of impairment exist at reporting period ends and, if required, determining recoverable amounts including assumptions and inputs thereto.

Intangible assets – The Company applies judgment to assess whether there are any indications that its intangible assets may be impaired. This assessment requires an assessment of external, internal and other indicators at the end of each reporting period.

4. Capital risk management

The Company manages its capital with the following objectives:

- to ensure sufficient financial flexibility to achieve the ongoing business objectives including funding of future growth opportunities; and
- to maximize shareholder return through enhancing the share value.

The Company monitors its capital structure and makes adjustments according to market conditions in an effort to meet its objectives given the current outlook of the business and financial markets in general. The Company may manage its capital structure by issuing new shares, repurchasing outstanding shares, or adjusting spending. The capital structure is reviewed by management and the Board of Directors on an ongoing basis.

The Company considers its capital structure to consist of share capital, contributed surplus, and deficit, which at March 31, 2022 totaled deficit of \$197,922 (December 31, 2021 - surplus of \$77,565). The Company reviews its working capital and forecasts its future cash flows based on operating expenditures, and other investing and financing activities. Selected information is provided to the Board of Directors of the Company. The Company is not subject to any capital requirements imposed by a lending institution.

Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Unaudited

5. Amounts receivable

		As at March 31, 2022	As at December 31, 2021		
Sales tax receivable (i)	\$	79,000	\$	88,155	
	\$	79,000	\$	88,155	

⁽i) Sales tax receivable is not past due.

6. Promissory note receivable

On March 5, 2019, the Company entered into a loan agreement in the amount of \$200,000 with 11103016 Canada Inc. ("11103016 Canada"). The loan is secured by 11103016 Canada's inventory and equipment, and bears interest rate of Prime Bank Rate plus 5% per annum, calculated monthly not in advance. The loan is repayable on or before March 5, 2020. The Company loaned an additional \$100,000 to 11103016 Canada in August 2019. On March 5, 2020, the Company extended the repayment date of the loan to December 31, 2020. In April 2021, the repayment date was extended to December 31, 2021, and in April 2022, the repayment date was further extended to December 31, 2022.

As at March 31, 2022, the Company was owed \$369,908 (December 31, 2021 - \$364,333) including accrued interest.

7. Plant and equipment

Cost		asehold ovement	s E	quipment		Total
Balance, December 31, 2020 Additions	\$	648,553 457,728	-	133,376 1,269,447		781,929 1,727,175
Balance, December 31, 2021 Additions	1	,106,281 20,826		1,402,823 5,068		2,509,104 25,894
Balance, March 31, 2022	\$ 1	,127,107	\$	1,407,891	\$	2,534,998
Accumulated depreciation		asehold ovement	s E	quipment		Total
Balance, December 31, 2020 Depreciation for the year	\$	152,762 186,798	\$	- 142,823	\$	152,762 329,621
Balance, December 31, 2021 Depreciation for the period		339,560 56,355		142,823 70,395		482,383 126,750
Balance, March 31, 2022	\$	395,915	\$	213,218	\$	609,133
Carrying value		asehold ovement	s E	quipment		Total
Balance, December 31, 2021 Balance, March 31, 2022	\$ \$	766,721 731,192		1,260,000 1,194,673		2,026,721 1,925,865
Dalatice, Match 31, 2022	Ψ	131,192	φ	1,134,073	φ	1,823,00

Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Unaudited

8. Right-of-use assets

Cost	Brantford facility
Balance, December 31, 2020, December 31, 2021 and March 31, 2022	\$ 3,316,387
Accumulated depreciation	Brantford facility
Balance, December 31, 2020 Depreciation for the year Balance, December 31, 2021 Depreciation for the period	\$ 490,761 329,316 820,077 82,329
Balance, March 31, 2022 Carrying value	\$ 902,406 Brantford facility
Balance, December 31, 2021 Balance, March 31, 2022	\$ 2,496,310 \$ 2,413,981

9. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities of the Company are principally comprised of amounts outstanding for purchases relating to general operating activities.

	As at March 31, 2022	De	As at ecember 31, 2021
Accounts payable Accrued liabilities	\$ 1,125,362 459,475	\$	1,142,992 387,864
Total accounts payable and accrued liabilities	\$ 1,584,837	\$	1,530,856

10. Promissory note payable

In August 2021, the Company obtained a \$225,000 secured loan from Quinsam Capital Corporation ("Quinsam"). The loan is repayable by December 31, 2021, bears interest at 10% per annum, and is secured by the Company's assets. As at March 31, 2022, the Company owed \$241,868 (December 31, 2021 - \$236,246) including accrued interest.

In connection therewith, the Company issued 750,000 warrants to Quinsam. Each warrant is exercisable for one common share of the Company at a price of \$0.15 per share for a period of 2 years. The 750,000 warrants were valued at \$37,300 as estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate - 0.47%; dividend yield - 0%; expected stock volatility - 199% and an expected life of 2 years.

In April 2022, the Company extended the repayment date to December 31, 2022. In consideration, the Company agreed to issue 500,000 shares of the Company to Quinsam.

Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Unaudited

11. Loans payable

(i) On July 7, 2020, the Company entered into a revolving line of credit agreement (the "LOC Agreement") with a third party lender ("Lender"), whereby the Company can obtain \$1,500,000 of revolving line of credit financing facility to be used exclusively for the purchase of the Company's business related equipment, deposits for construction work and tenant's improvement on the Company's Brantford facility, or for security, rental payments, taxes and insurance related thereto. The funds advanced under the LOC bore interest at a rate of 10% per annum. During the year ended December 31, 2021 the LOC Agreement was amended to terminate on April 30, 2022 and bear interest rate at a rate of 7% per annum effective September 8, 2021.

In consideration for lending the funds advanced, the Company is to issue to the Lender one unit of the Company for each full \$1 advanced. Each unit will consist of one common share of the Company and one common share purchase warrant. Each warrant shall entitle the Lender to purchase one common share of the Company at the greater of \$0.15 and a 25% premium to the market price of the Company's common shares at the time of issuance and expire in 2 years.

In consideration, the Company issued:

- On July 20, 2020, 250,000 units valued at \$48,250, which consisted of 250,000 common shares valued at \$26,250 and 250,000 warrants valued at \$22,000 as estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate 0.27%; dividend yield 0%; expected stock volatility 208% and an expected life of 2 years; and
- On September 16, 2020, 161,688 units valued at \$32,786, which consisted of 161,688 common shares valued at \$17,786 and 161,688 warrants valued at \$15,000 as estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate 0.26%; dividend yield 0%; expected stock volatility 204% and an expected life of 2 year.

During the during the year ended December 31, 2021, the Company issued 2,755,900 common shares to settle \$220,472 of the LOC.

For the three months ended March 31, 2022, \$nil (three months ended March 31, 2021 - \$nil) was expensed to debt issue cost. As at March 31, 2022, the Company owed \$238,435 (December 31, 2021 - \$233,720) including accrued interest.

(ii) In April 2020, the Company received \$40,000 under the Canada Emergency Business Account (CEBA) program. 25% of the loan is forgivable if repaid by December 31, 2022. The loan accrues no interest until December 31, 2022, and thereafter converts to a 3-year term loan with a 5% annual interest rate. Any portion of the loan is repayable without penalty at any time prior to December 31, 2025.

On January 12, 2022, the Government of Canada announced that the repayment deadline for CEBA loans to qualify for partial loan forgiveness is being extended from December 31, 2022 to December 31, 2023 for all eligible borrowers in good standing. Repayment on or before the new deadline of December 31, 2023 will result in loan forgiveness of up to a third of the value of the loans (ie. up to \$20,000 with respect to the CEBA Loans). Conversely, if any such loans are not repaid in full by December 31, 2023, they will automatically renew with a maturity date of December 31, 2025, subject to interest at 5% per annum, commencing on January 1, 2024.

City View Green Holdings Inc.
Notes to Condensed Interim Consolidated Financial Statements
Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) **Unaudited**

12. Lease liabilities

	Brantford facility
Balance, December 31, 2020	\$ 3,095,400
Interest expense	394,405
Lease payments	(531,816)
Balance, December 31, 2021	2,957,989
Interest expense	95,734
Lease payments	(132,955)
	2,920,768
Less: current portion	(161,516)
Balance, March 31, 2022	\$ 2,759,252

13. Share capital

(a) **Authorized share capital**

Unlimited number of common shares, with no par value.

Common shares issued

Balance, December 31, 2020 247,461,530 \$ 28,500,1	36
Dalatice, Describer 51, 2020 Ψ 20,000, 1	
Units issued for cash (i) 11,400,000 570,0	
Fair value of warrants (i) - (155,0	
Common shares issued for debt settlement (ii) 1,082,197 119,0	42 [°]
Issued on exercise of warrants 100,000 7,4)0
Balance, March 31, 2021 260,043,727 \$ 29,041,6	28
Balance, December 31, 2021 283,412,270 \$ 30,298,5	77
Units issued for cash (iii) 9,600,000 480,0)0
Fair value of warrants (iii) - (201,3)0)
Common shares issued for debt settlement (iv) 1,261,784 56,7	30
Balance, March 31, 2022 294,274,054 \$ 30,634,0	57

Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Unaudited

13. Share capital (continued)

(b) Common shares issued (continued)

(i) On January 8, 2021, the Company completed the second and final tranche of its non-brokered private placement, pursuant to which it issued an aggregate of 11,400,000 units for aggregate gross proceeds of \$570,000. Each unit is composed of one common share of the Company and one half share purchase warrant. Each warrant entitles the holder to purchase one share at a price of \$0.05 per warrant for a period of 2 years from the date of issuance, subject to an acceleration provision whereby, after four months and one day from their date of issuance, if the closing price of the shares on the CSE is equal to or exceeds \$0.15 for a period of 10 consecutive trading days, then the Company may, at its option, accelerate the expiry date of the warrants to the date which is 30 days following the date upon which notice of the accelerated expiry date is provided by the Company to the holders of the warrants. The Company did not incur any share issuance costs.

The 5,700,000 warrants issued were assigned a value of \$155,000 using the Black-Scholes valuation model using the following assumptions: weighted average unit price of \$0.05, risk-free rate of return of 0.19%, expected volatility of 200% based on historical trends, dividend yield of 0%, and expected life of 2 years.

- (ii) On January 29, 2021, the Company issued 1,082,197 common shares to certain creditors of the Company to settle an aggregate debt of \$91,987. The common shares issued had a deemed price of \$0.11 based on the fair value and as a result, the Company recognized a loss on settlement of debt of \$27,055.
- (iii) On March 17, 2022, the Company closed a non-brokered private placement, pursuant to which it issued an aggregate of 9,600,000 units for aggregate gross proceeds of \$480,000. Each unit is comprised of one common share of the Company and one share purchase warrant. Each warrant entitles the holder to purchase one common shares of the Company at a price of \$0.10 per share for a period of 2 years from the closing date, subject to acceleration from and after the date that is fourth months and one day after the closing date, if the closing price of the Company's common shares on the CSE is equal to or exceeds \$0.11 for 5 consecutive trading days, at which time the Company may accelerate the expiry date of the warrants to the date that is 30 following the date on which the Company issues notice to all the warrant holders of the new expiry date.

The 9,600,000 warrants issued were assigned a value of \$201,300 using the Black-Scholes valuation model using the following assumptions: unit price of \$0.05, weighted average risk-free rate of return of 1.89%, expected volatility of 198% based on historical trends, dividend yield of 0%, and expected life of 2 years.

(iv) On March 17, 2022, the Company also issued 1,261,784 common shares to certain creditors of the Company to settle an aggregate debt of \$88,325. The common shares issued had a deemed price of \$0.045 based on the fair value and as a result, the Company recognized a gain on settlement of debt of \$31,545.

Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Unaudited

14. Stock options

The Company has a Share Option Plan (the "Plan") under which it is authorized to grant options to purchase common shares of the Company to directors, senior officers, employees and/or consultants of the Company. The aggregate number of shares of the Company which may be issued and sold under the Plan will not exceed 15% of the total number of common shares issued and outstanding from time to time. Share options are granted with a maximum term of ten years with vesting requirements at the discretion of the Board of Directors.

Company records a charge to the statement of loss and comprehensive loss using the Black-Scholes fair valuation option pricing model with respect to a share option grant. The valuation is dependent on a number of estimates, including the risk free interest rate, the level of share volatility, together with an estimate of the level of forfeiture. The level of share volatility is calculated with reference to the historic traded daily closing share price at the date of issue. Option pricing models require the input of highly subjective assumptions including the expected price volatility. Changes in the subjective input assumptions can materially affect the fair value estimate, and therefore the existing models do not necessarily provide a reliable measure of the fair value of the Company's share purchase options.

	Number of stock options	Weighted average exercise price		
Balance, December 31, 2020	29,789,732	\$	0.23	
Granted (i)	600,000		0.12	
Balance, March 31, 2021	30,389,732	\$	0.22	
Balance, December 31, 2021	34,289,732	\$	0.21	
Granted (ii)	500,000		0.10	
Cancelled	(1,100,000)		0.10	
Balance, March 31, 2022	33,689,732	\$	0.21	

- (i) On February 18, 2021, the Company granted 600,000 stock options to consultants of the Company exercisable at \$0.12 per common share. The options vest immediately and expire in 3 years. The grant date fair value of \$66,000 was assigned to the stock options as estimated by using the Black-Scholes valuation model with the following assumptions: share price of \$0.12, expected dividend yield of 0%, expected volatility of 200%, risk-free rate of return of 0.27% and an expected maturity of 3 years. For the three months ended March 31, 2022, \$nil (three months ended March 31, 2021 \$66,000) was expensed to share-based compensation.
- (ii) On March 16, 2022, the Company granted 500,000 stock options to a consultant of the Company exercisable at \$0.10 per common share. The options vest immediately and expire in 3 years. The grant date fair value of \$18,500 was assigned to the stock options as estimated by using the Black-Scholes valuation model with the following assumptions: share price of \$0.045, expected dividend yield of 0%, expected volatility of 177%, risk-free rate of return of 1.90% and an expected maturity of 3 years. For the three months ended March 31, 2022, \$18,500 (three months ended March 31, 2021 \$nil) was expensed to share-based compensation.

Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Unaudited

14. Stock options (continued)

The following table reflects the actual stock options issued and outstanding as of March 31, 2022:

Francis data	Exercise	Weighted average remaining contractual	Number of options	Number of options vested	
Expiry date	price (\$)	life (years)	outstanding	(exercisable)	
January 9, 2023	0.375	0.78	1,646,400	1,646,400	
February 18, 2024	0.12	1.92	600,000	600,000	
February 28, 2024	0.75	1.92	600,000	600,000	
February 28, 2024	0.25	1.92	4,560,000	4,560,000	
February 28, 2024	0.75	1.92	3,013,332	3,013,332	
June 3, 2024	0.15	2.18	1,850,000	1,850,000	
July 24, 2024	0.18	2.32	300,000	300,000	
October 4, 2024	0.15	2.52	3,300,000	3,300,000	
December 22, 2024	0.10	2.73	3,500,000	3,500,000	
March 16, 2025	0.10	2.96	500,000	500,000	
September 14, 2025	0.10	3.46	13,620,000	13,620,000	
October 7, 2025	0.10	3.52	200,000	200,000	
	0.21	2.67	33,689,732	33,689,732	

15. Warrants

	Number of warrants	Weighted average exercise price	
Balance, December 31, 2020	39,888,021	\$	0.10
Issued (i)	5,700,000		0.10
Expired	(1,000,000)		0.15
Exercised	(100,000)		0.05
Balance, March 31, 2021	44,488,021	\$	0.10
Balance, December 31, 2021	59,385,377	\$	0.11
Issued (i)	9,600,000		0.10
Balance, March 31, 2022	68,985,377		0.11

⁽i) During the three months ended March 31, 2022, the Company issued an aggregate of 9,600,000 warrants (three months ended March 31, 2021 - 5,700,000 warrants) as a part of its non-brokered private placements. See note 13.

City View Green Holdings Inc.
Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Ùnaudited

Warrants (continued) 15.

The following table reflects the warrants issued and outstanding as of March 31, 2022:

Expiry date	Exercise price (\$)	Warrants outstanding	
A = =: 20 2022 (ii)		6.700.000	
April 30, 2022 (ii)	0.15	6,700,000	
July 20, 2022	0.15	250,000	
September 17, 2022	0.15	161,688	
November 15, 2022	0.30	2,001,333	
November 30, 2022	0.20	500,000	
December 13, 2022	0.20	2,400,000	
December 23, 2022	0.20	125,000	
December 24, 2022	0.10	2,100,000	
January 8, 2023	0.10	5,700,000	
April 30, 2023	0.05	9,600,000	
May 22, 2023	0.05	6,000,000	
June 17, 2023	0.05	7,400,000	
November 3, 2023	0.10	550,000	
July 30, 2024	0.18	1,000,000	
April 9, 2023	0.15	1,946,250	
April 30, 2023	0.15	656,250	
August 11, 2023	0.15	9,044,142	
August 11, 2023	0.15	750,000	
October 8, 2023	0.15	2,500,714	
March 17, 2024	0.10	9,600,000	
	0.11	68,985,377	

⁽ii) Subsequent to March 31, 2022, 6,700,000 warrants expired unexercised.

Notes to Condensed Interim Consolidated Financial Statements Three Months Ended March 31, 2022 (Expressed in Canadian Dollars) Unaudited

16. Related party balances and transactions

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. The following related party transactions were conducted in the normal course of operations and were made on an arm's length basis:

	E Ma	Three Months Thre Ended March 31, M 2022		
Consulting Professional fees	\$	71,250 11,470	\$	37,500 11,061
	\$	82,720	\$	48,561

As at March 31, 2022, \$332,671 (December 31, 2021 - \$269,469) included in accounts payable and accrued liabilities was payable to key management personnel.

As at March 31, 2022, the Company owes a director of the Company \$20,000 (December 31, 2021 - \$20,000). The advance is non-interest bearing and repayable on demand.

During the three months ended March 31, 2022, the directors of the Company subscribed for an aggregate of 2,000,000 units for gross proceeds of \$100,000 (three months ended March 31, 2021 - an aggregate of 1,200,000 units for gross proceeds of \$60,000).

17. Loss per share

For the three months ended March 31, 2022, basic and diluted loss per share has been calculated based on the loss attributable to common shares of \$555,767 (three months ended March 31, 2021 - \$521,431) and weighted average number of common shares outstanding of 285,101,881 (three months ended March 31, 2021 - 258,649,464). Diluted loss per share did not include the effect of stock options as they are anti-dilutive.

18. Subsequent events

On April 21, 2022, the Company received its cannabis research licence under Health Canada's Cannabis Act and Cannabis Regulations. The licence permits the Company to conduct controlled human sensory (taste) trials of cannabis infused products.

On May 2, 2022, the Company issued 3,250,000 share purchase warrants to a consultant in partial consideration for consulting advisory services. The warrants expire on December 31, 2022 and are each exercisable for one common share of the Company at a price of \$0.10 per share.

The Company also issued 600,000 common shares to a certain creditor of the Company to settle debt of \$42,000.